L-DOPA regulates α-synuclein accumulation in experimental parkinsonism.

Marc DeffainsMarie-Hélène CanronMargaux TeilQin LiBenjamin Dehay Erwan Bezard Pierre Olivier Fernagut

Published in: Neuropathology and applied neurobiology (2020)

Dopamine replacement therapy can dramatically ameliorate α-synuclein pathology in the MPTP NHP model of PD. Therefore, patient's dopaminergic medication should be systematically considered when assessing α-synuclein as a biomarker for diagnosis, monitoring disease progression and response to disease-modifying treatments.

Keyphrases

replacement therapy
smoking cessation
case report
healthcare
parkinson disease
uric acid
emergency department
drug induced
adverse drug